z-logo
open-access-imgOpen Access
A phase 1b/pharmacokinetic trial of PTC299, a novel post-transcriptional VEGF inhibitor, for AIDS-related Kaposi’s sarcoma: AIDS Malignancy Consortium trial 059
Author(s) -
Rachel Bender Ignacio,
Jeannette Y. Lee,
Michelle A. Rudek,
Dirk P. Dittmer,
Richard F. Ambinder,
Susan E. Krown,
David M. Aboulafia,
Robert A. Baiocchi,
Elizabeth Y. Chiao,
Bruce J. Dezube,
Ronald T. Mitsuyasu,
Erin Reid,
Bruce Shiramizu,
Joseph A. Sparano,
Anil Tulpule,
Anthony Eason,
Veenadhari Chavakula,
Julia Lynne
Publication year - 2016
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/q862-w217
Subject(s) - malignancy , sarcoma , vegf receptors , human immunodeficiency virus (hiv) , medicine , oncology , pharmacokinetics , clinical trial , virology , pathology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom